Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Regen BioPharma Inc logo — company profile

Regen BioPharma Inc

Founded 2012 2 employees Biotechnology, Health Care

General Information

Company Name Regen BioPharma Inc
Founded Year 2012
Employees 2
Industries Biotechnology, Health Care
Social

Get notified when Regen BioPharma Inc moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Regen BioPharma Inc

Regen BioPharma, Inc. is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space. The company is developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal products under development include HemaXellarate I, HemaXellerate II, dCellVax, and DiffronC. HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell-based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation. The company, founded in 2012, is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. Regen BioPharma operates in the biotechnology and healthcare industries. The company's dedication to pursuing regenerative medicine solutions and developing innovative therapies for complex medical conditions positions it as a compelling prospect for venture capital investment. The potential of its products, such as HemaXellarate I and dCellVax, to address critical medical needs, especially in the treatment of damaged bone marrow and cancer, presents an attractive investment opportunity. With a strong focus on the burgeoning field of regenerative medicine and a diversified development pipeline, Regen BioPharma offers promising potential for growth and positive impact in the biotechnology and healthcare sectors.

Taxonomy: regenerative medicine, stem cell research, aplastic anemia, gene silencing therapy, cellular therapy, immunology, immunotherapy, pre-clinical trials, clinical trials, small molecule therapies, cancer treatment, autoimmune disorders, publicly traded company, OTCQB

No funding data available for Regen BioPharma Inc yet.

Get notified when Regen BioPharma Inc raises funding

Regen BioPharma Inc Alternatives & Competitors

Regen BioPharma Inc vs
Benitec Biopharma Inc.
Benitec Biopharma Inc. United States

Silencing genes for life

Post Ipo Equity
16 employees
Biotechnology, Health Care
Regen BioPharma Inc vs
Castle Institutional Review Board (Castle IRB), a subsidiary of Sabai Global
Castle Institutional Review Board (Castle IRB), a subsidiary of Sabai Global United States

Independent IRB. Gene & cell therapy. Rare disease. Expert Ethics Board. Concierge support/consultin...

9 employees
Health Care
Regen BioPharma Inc vs
Tmunity Therapeutics
Tmunity Therapeutics

Pioneering the future of immunotherapy through innovative T cell engineering to tackle a diverse arr...

Acquired
12 employees
Biotechnology, Health Care

FAQ About Regen BioPharma Inc

Regen BioPharma, Inc. is a biotechnology company. The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space. The Company is also focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal prod...
Regen BioPharma Inc was founded in 2012.
Regen BioPharma Inc operates in the following industries: Biotechnology, Health Care.
Regen BioPharma Inc has approximately 2 employees.
Top alternatives and competitors to Regen BioPharma Inc include Benitec Biopharma Inc., Castle Institutional Review Board (Castle IRB), a subsidiary of Sabai Global, Tmunity Therapeutics, American Gene Technologies® International Inc., American Society of Gene & Cell Therapy. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Regen BioPharma Inc and Benitec Biopharma Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Regen BioPharma Inc and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy